SILIQ (BRODALUMAB) APPROVED BY US FDA
16 February 2017, 12 noon GMT SILIQ (BRODALUMAB) APPROVED BY THE US FDA FOR ADULT PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Approval triggers $130 million milestone payment to AstraZeneca from US Partner Valeant Pharmaceuticals AstraZeneca's partner Valeant Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Siliq (brodalumab) injection for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other